Ulrik Nielsen

Ulrik Nielsen has an extensive background in the biotech industry, having served as CEO of Silver Creek Pharmaceuticals and founder, chairman, and president of Torque (now Repertoire Immune Medicines). Ulrik is currently a board member at Alloy Therapeutics.

Nielsen received their PhD from the University of California, San Francisco, where their research focused on cell biology, engineering, and computational biology. Ulrik then completed a postdoc at MIT before joining Merrimack Pharmaceuticals as a postgraduate researcher.

At Silver Creek Pharmaceuticals, Nielsen led the development of a new platform of biotherapeutics called Smart Growth FactorsTM. These drugs promote resilience and regeneration of specific organs while minimizing unwanted effects in other tissues.

As founder, chairman, and president of Torque, Nielsen oversaw the development of a new class of immunotherapies called CAR T cells. These treatments have shown promising results in clinical trials for the treatment of various cancers.

Alloy Therapeutics is a biotechnology company that is developing novel therapies for the treatment of rare genetic diseases.

Ulrik Nielsen was educated as a Doctor of Philosophy in Molecular Biology at Københavns Universitet - University of Copenhagen. Ulrik also attended Harvard Business School.